Boston Scientific Corp.
Revenue Breakdown
| Fiscal Year | Endoscopy | Urology | Neuromodulation | Cardiac Rhythm Management | Electrophysiology | Interventional Cardiology | Peripheral Interventions | Watchman | Interventional Cardiology & Vascular Therapies | Interventional Oncology & Embolization | Specialty Pharmaceuticals/Other |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2024 | $2.69B | $2.20B | $1.11B | $2.28B | $1.90B | $2.65B | $2.41B | $1.52B | — | — | $0 |
| FY2025 | $2.92B | $2.71B | $1.20B | $2.33B | $3.33B | — | — | $1.96B | $4.64B | $996.0M | — |